BioCardia to Present at Maxim Group’s Inaugural Emerging Growth Virtual Conference

Rhea-AI Summary

BioCardia (Nasdaq: BCDA) announces CEO Dr. Peter Altman will present at the Maxim Group’s Inaugural Emerging Growth Virtual Conference, scheduled for March 17-19, 2021. Dr. Altman's live fireside chat is set for 3:30 PM ET on March 19. Registered attendees can also access a corporate presentation on the conference website and request a 1x1 meeting with Dr. Altman post-conference. BioCardia focuses on developing regenerative therapies for cardiovascular disease, with notable products like the CardiAMP cell therapy and the Helix Biotherapeutic Delivery System.

SAN CARLOS, Calif., March 15, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, announces that CEO Dr. Peter Altman will present at Maxim Group’s Inaugural Emerging Growth Virtual Conference to be held March 17-19, 2021.

Investors can view Dr. Altman’s live fireside chat presentation at 3:30pm ET on March 19 and once registered for the conference here, can listen to a corporate presentation which will be available on the conference website. Investors can also request a 1x1 meeting with Dr. Altman to be arranged following the conclusion of the conference.

About BioCardia

BioCardia, headquartered in San Carlos, California, is developing regenerative biologic therapies to treat cardiovascular and respiratory disease. CardiAMP autologous and Neurokinin-1 Receptor Positive allogenic cell therapies are the Company’s biotherapeutic platforms in clinical development. The Company's products include the Helix Biotherapeutic Delivery System and its steerable guide and sheath catheter portfolio. BioCardia also partners with other biotherapeutic companies to provide its Helix system and clinical support for their programs studying therapies for the treatment of heart failure, chronic myocardial ischemia, and acute myocardial infarction. For more information, visit www.BioCardia.com.

INVESTOR CONTACT:
David McClung, Chief Financial Officer
investors@BioCardia.com
(650) 226-0120

MEDIA CONTACT:
Michelle McAdam, Chronic Communications, Inc.
michelle@chronic-comm.com
(310) 545-6654

FAQ

When will BioCardia present at the Maxim Group's Emerging Growth Virtual Conference?

BioCardia will present at Maxim Group's Emerging Growth Virtual Conference on March 17-19, 2021, with Dr. Altman's presentation at 3:30 PM ET on March 19.

How can investors access the BioCardia presentation during the conference?

Investors can view Dr. Altman's presentation live by registering for the conference on its official website.

What is BioCardia's focus in the healthcare sector?

BioCardia focuses on developing regenerative therapies for cardiovascular and respiratory diseases.

What products does BioCardia offer?

BioCardia offers products like the CardiAMP autologous cell therapy and the Helix Biotherapeutic Delivery System.

Can investors request a meeting with Dr. Altman after the conference?

Yes, investors can request a 1x1 meeting with Dr. Altman to be arranged after the conference.